Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.

Decker T, Fischer G, Bücke W, Bücke P, Stotz F, Grüneberger A, Gropp-Meier M, Wiedemann G, Pfeiffer C, Peschel C, Götze K.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1945-50. doi: 10.1007/s00432-012-1258-3. Epub 2012 Jul 4.

PMID:
22760213
2.

Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.

Park IH, Han HS, Lee H, Lee KS, Kang HS, Lee S, Kim SW, Jung S, Ro J.

Ann Oncol. 2012 Sep;23(9):2283-9. doi: 10.1093/annonc/mds006. Epub 2012 Feb 29.

PMID:
22377562
3.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N.

N Engl J Med. 2010 Jun 3;362(22):2053-65. doi: 10.1056/NEJMoa0909638.

4.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
5.

FOXP3 expression and overall survival in breast cancer.

Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A.

J Clin Oncol. 2009 Apr 10;27(11):1746-52. doi: 10.1200/JCO.2008.17.9036. Epub 2009 Mar 2.

PMID:
19255331
6.

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL.

J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
18612148
7.

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S.

J Clin Oncol. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787.

PMID:
18165639
8.
9.
10.

Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.

Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G.

J Clin Oncol. 2007 Feb 1;25(4):405-10. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334.

PMID:
17264336
11.

Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH.

J Clin Oncol. 2006 Dec 1;24(34):5373-80.

PMID:
17135638
12.

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.

Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.

Clin Cancer Res. 2006 Nov 1;12(21):6573-84.

13.

Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.

Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE.

J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15.

PMID:
17018787
14.

Estrogen carcinogenesis in breast cancer.

Yager JD, Davidson NE.

N Engl J Med. 2006 Jan 19;354(3):270-82. Review. No abstract available.

PMID:
16421368
15.
16.
17.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
18.

Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment.

Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SF, Offner H.

J Immunol. 2004 Aug 15;173(4):2227-30.

19.

Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells.

Stassen M, Jonuleit H, Müller C, Klein M, Richter C, Bopp T, Schmitt S, Schmitt E.

J Immunol. 2004 Jul 1;173(1):267-74.

20.

An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1.

Elkin M, Orgel A, Kleinman HK.

J Natl Cancer Inst. 2004 Jun 2;96(11):875-8.

PMID:
15173272

Supplemental Content

Support Center